Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2025 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive...
March 03, 2025 07:00 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
February 25, 2025 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
January 21, 2025 07:00 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters highlight the safety data, tolerability data, and antitumor...
December 20, 2024 07:00 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Provides Business and Operational Update

-- Dispensed applicator units in the fourth quarter of 2024 have exceeded the complete prior quarter even with significant cost reductions in sales and operational infrastructure -- Observed...
December 09, 2024 16:15 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
December 06, 2024 08:00 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
November 21, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Announces Pricing of $42.0 Million Public Offering

WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
November 20, 2024 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Announces Proposed Public Offering

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
November 04, 2024 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– ...